Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
23.05.23
/
50%
€21.20
Target price
23.05.24
€23.22
Performance (%)
0.94%
End price
24.05.24
€21.40
Summary
This prediction ended on 24.05.24 with a price of €21.40. The BUY prediction by The_Goldman_Sachs_Gr for Myriad Genetics closed nearly unchanged. The_Goldman_Sachs_Gr has a follow-up prediction for Myriad Genetics where he still thinks Myriad Genetics is a Buy. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Myriad Genetics | -8.936% | -8.936% | -63.729% |
| iShares Core DAX® | 1.085% | -1.655% | 13.297% |
| iShares Nasdaq 100 | -1.665% | -3.137% | 2.218% |
| iShares Nikkei 225® | 3.863% | 6.947% | 22.818% |
| iShares S&P 500 | 0.111% | -1.320% | 1.445% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "sell" rating to a "buy" rating. They now have a $25.00 price target on the stock, up previously from $18.00.
Ratings data for MYGN provided by MarketBeat
In the thread Trading Myriad Genetics
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten